GlassScriptPhysician profile
Sally B Bowa
NPI 1932532991
$117,013.09
in general payments reported to CMS, 2019-2025
22 companies · $29K in 2025
The $29K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,100 · 2022: $28K · 2023: $25K · 2024: $28K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Travel and Lodging: $30K · Consulting Fee: $8,615 · Food and Beverage: $7,695 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,231.67 |
| Travel and Lodging | $30,377.01 |
| Consulting Fee | $8,614.50 |
| Food and Beverage | $7,694.99 |
| Education | $165.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $52,455.52 | 2021-2025 | |
| Genzyme Corporation | $19,870.69 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $15,916.00 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $13,996.69 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $4,398.35 | 2021-2024 | Zeposia |
| Medical Device Business Services, INC. | $4,105.00 | 2021 | |
| Janssen Scientific Affairs, LLC | $3,606.86 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $939.74 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $352.44 | 2022-2025 | Epclusa, Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $307.35 | 2022-2024 | Entyvio |
| Ardelyx, INC. | $262.89 | 2023 | Ibsrela |
| Pfizer INC. | $187.23 | 2021-2024 | |
| Ferring Pharmaceuticals INC. | $161.87 | 2023 | Rebyota |
| Janssen Pharmaceuticals, INC | $137.23 | 2021 | |
| Novo Nordisk INC | $109.28 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $107.51 | 2024 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.04 | 2023 | Cyltezo |
| Ethicon US, LLC | $18.48 | 2023 | Linx Reflux Management System |
| Intercept Pharmaceuticals, INC. | $17.30 | 2025 | |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Madrigal Pharmaceuticals | $14.30 | 2025 | Rezdiffra |
| Enterra Medical, INC. | $13.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sally Bowa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.